In colorectal cancer, treatment with Claramine abolished IL-13-induced cell adhesion to Matrigel at a similar extent to the use of a blocking IL13Rα2 antibody (clone 47) [36], suggesting that both treatments are likely blocking the same pathway (Figure 5B). The gene discussed is IL13; the disease is colorectal cancer.